Aspira Women's Health Inc
NASDAQ:AWH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aspira Women's Health Inc
Revenue
Aspira Women's Health Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aspira Women's Health Inc
NASDAQ:AWH
|
Revenue
$9.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$20.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Revenue
$6.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$25.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$45.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$10.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Aspira Women's Health Inc
Glance View
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 106 full-time employees. The company went IPO on 2000-09-29. Its products include OVA1 and Overa, OVA1plus, Aspira GenetiX and Aspira Synergy. OVA1 is a blood test that is intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical, and Overa is intended to maintain OVA1’s high sensitivity. OVA1plus is a reflex test performed for those OVA1 test results that are in the intermediate risk range. Aspira GenetiX is a genetic test for gynecologic cancer risk, with a focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers. Aspira Synergy is an en-suite, cloud-based technology transfer solution that provides an end-to-end solution from specimen collection to a customized white-label report for clinical laboratories to internalize testing of its products.
See Also
What is Aspira Women's Health Inc's Revenue?
Revenue
9.2m
USD
Based on the financial report for Dec 31, 2024, Aspira Women's Health Inc's Revenue amounts to 9.2m USD.
What is Aspira Women's Health Inc's Revenue growth rate?
Revenue CAGR 10Y
14%
Over the last year, the Revenue growth was 0%. The average annual Revenue growth rates for Aspira Women's Health Inc have been 10% over the past three years , 15% over the past five years , and 14% over the past ten years .
